GLP-1 Clinics (Semaglutide & Tirzepatide)

Semaglutide (Ozempic, Wegovy) is a GLP-1 agonist. Tirzepatide (Mounjaro, Zepbound) is a dual GLP-1/GIP agonist — clinical trials show greater average weight loss (~20% vs ~15%).

FDA-registered 503A/503B compounding pharmacies are regulated. Quality varies — pick a provider that names its pharmacy and shares lot testing.

Yes — every provider on Kyzen One offering GLP-1 supports telehealth intake, lab orders, and prescription shipping.

Compounded semaglutide programs average $149–$299/month all-in. Tirzepatide compounded programs typically run $299–$499/month. Branded Wegovy and Zepbound run higher unless covered by insurance.

The active ingredients are FDA approved; compounded formulations are not separately FDA approved. They are dispensed by state-licensed 503A or federally-registered 503B pharmacies regulated by the FDA.

Most patients see appetite suppression within the first 1–2 weeks and 1–2% body-weight reduction per month once titrated to therapeutic dose (typically week 8–12).

Most patients regain weight after stopping unless they continue lifestyle changes, sometimes paired with a maintenance dose. The best clinics include a transition plan in their program.

Generally yes, but oral medications may be absorbed more slowly. Always disclose your full medication list during intake — your clinician will adjust timing where needed.

Yes. Telehealth visits, lab work, and most medically necessary prescriptions are HSA and FSA eligible. Save your receipts and your annual care summary.

Some — including testosterone for TRT — yes, under DEA telemedicine rules. Other controlled categories are limited and may require an in-person visit first.

All providers in our directory are HIPAA compliant. Visits happen over encrypted video or secure messaging, and labs ship in plain packaging.